Myoneurin Inhibitors
Myoneurin, a protein encoded by the MYNN gene, plays a multifaceted role in cellular processes, with its primary function centered on the regulation of muscle development and function. As a member of the BTB/POZ domain-containing protein family, myoneurin exhibits diverse molecular interactions and functions, contributing to various aspects of muscle biology. One of its key roles is its involvement in myogenesis, where it participates in the differentiation of myoblasts into mature muscle fibers by regulating the expression of genes critical for muscle development and contractile function. Myoneurin also functions as a transcriptional regulator, modulating the activity of target genes involved in muscle-specific processes such as sarcomere organization, muscle fiber composition, and contractile protein expression. Moreover, emerging evidence suggests that myoneurin may possess additional functions beyond muscle biology, influencing other cellular pathways and physiological processes, although further elucidation is warranted to fully comprehend its broader biological significance.
Inhibition of myoneurin presents a promising avenue for exploring its physiological roles and investigating strategies for conditions associated with dysregulated muscle function. Targeting myoneurin activity could be achieved through various mechanisms, including interference with its protein-protein interactions, modulation of its transcriptional regulatory functions, or disruption of its subcellular localization. Strategies aimed at inhibiting myoneurin could involve the development of small molecules or peptides designed to selectively bind to specific regions of the protein, thereby disrupting its association with binding partners or interfering with its ability to regulate target gene expression. Additionally, genetic approaches such as RNA interference or gene editing techniques could be employed to suppress MYNN expression, effectively attenuating myoneurin function and elucidating its biological roles in a controlled manner.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC. As Myoneurin is a protein known to interact with proteins involved in PKC signaling pathways, the inhibition of PKC by Staurosporine can lead to a decrease in the functional activities of Myoneurin. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, a key kinase in several signaling pathways. Given that Myoneurin interacts with proteins downstream of PI3K, LY294002 can impede the kinase's function, thereby indirectly reducing Myoneurin's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is upstream of ERK in the MAPK pathway. As Myoneurin can interact with proteins in the MAPK pathway, blocking MEK and thus reducing ERK activation can indirectly lead to the inhibition of Myoneurin. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK, which is involved in actin cytoskeleton reorganization. Given that Myoneurin is associated with proteins that regulate actin remodeling, inhibiting ROCK can indirectly reduce Myoneurin's functional activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases, which interact with proteins containing SH3 domains like Myoneurin. Therefore, PP2 can indirectly inhibit Myoneurin's function by blocking the activation of proteins with which it interacts. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, a kinase involved in various signaling pathways. As Myoneurin interacts with proteins that are downstream targets of JNK, inhibiting JNK can indirectly lead to a decrease in Myoneurin's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Given that Myoneurin can interact with proteins involved in MAPK signaling, SB203580 can inhibit p38 MAPK, leading to a decrease in Myoneurin's functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. As Myoneurin interacts with proteins that are downstream targets of PI3K, inhibiting PI3K by Wortmannin can lead to a decrease in Myoneurin's functional activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. As Myoneurin can interact with proteins phosphorylated by tyrosine kinases, Genistein can inhibit these kinases, leading to a decrease in Myoneurin's functional activity. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
AG-1478 is an inhibitor of EGFR tyrosine kinase. As Myoneurin can interact with proteins phosphorylated by EGFR, inhibiting EGFR by AG-1478 can lead to a decrease in Myoneurin's functional activity. | ||||||